|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Levemir
|
|
gptkbp:activities
|
increases glucose uptake
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2005
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Levemir
|
|
gptkbp:class
|
gptkb:Company
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:competitors
|
gptkb:insulin_glargine
gptkb:insulin_lispro
gptkb:insulin_aspart
insulin regular
|
|
gptkbp:contraindication
|
hypersensitivity to insulin detemir
|
|
gptkbp:developed_by
|
gptkb:Novo_Nordisk
|
|
gptkbp:dosage_form
|
individualized
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:education
|
exercise recommendations
proper injection technique
recognizing hypoglycemia
dietary considerations
|
|
gptkbp:form
|
vials
pre-filled pens
|
|
gptkbp:formulation
|
gptkb:software_framework
|
|
gptkbp:frequency
|
once or twice daily
|
|
gptkbp:has_ability
|
100 units/m L
200 units/m L
|
|
gptkbp:highest_point
|
6-8 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
insulin detemir
|
|
gptkbp:ingredients
|
C29 H46 N6 O5
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:ACE_inhibitors
beta-blockers
thiazolidinediones
|
|
gptkbp:invention
|
gptkb:2023
patented
|
|
gptkbp:is_used_for
|
diabetes management
|
|
gptkbp:lifespan
|
5-7 hours
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
1-2 hours
|
|
gptkbp:research_focus
|
cost-effectiveness
patient adherence
long-term safety
improving glycemic control
|
|
gptkbp:safety_features
|
blood glucose levels
Hb A1c levels
|
|
gptkbp:sales
|
billions of dollars
|
|
gptkbp:side_effect
|
injection site reactions
hypoglycemia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type
|
long-acting insulin
|
|
gptkbp:weight
|
614.78 g/mol
|